After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the ...